Updating the landscape of direct-to-consumer pharmacogenomic testing

Abstract

Pharmacogenomics has identified important drug–gene interactions that affect the safety and efficacy of medications. Direct-to-consumer genetic testing, when first introduced, included some pharmacogenomic-related genes. The current landscape of pharmacogenomic direct-to-consumer testing is reviewed. Prior published reviews of the literature were updated through February 2017 and a scan of the current availability of direct-to-consumer genomic testing by companies was conducted. Results of the review demonstrate a shift toward physician-approved ordering.

Keywords:

• pharmacogenomics
• direct-to-consumer testing

Disclosure

The authors report no conflicts of interest in this work.